Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4225252
Disease: IMMUNODEFICIENCY 45
IMMUNODEFICIENCY 45 		0.700 CausalMutation disease CLINVAR
CUI: C4225252
Disease: IMMUNODEFICIENCY 45
IMMUNODEFICIENCY 45 		0.700 Biomarker disease CTD_human
CUI: C0019163
Disease: Hepatitis B
Hepatitis B 		0.340 Biomarker disease CTD_human
CUI: C1864880
Disease: HEPATITIS B VIRUS, SUSCEPTIBILITY TO
HEPATITIS B VIRUS, SUSCEPTIBILITY TO 		0.100 SusceptibilityMutation disease CLINVAR
CUI: C0013080
Disease: Down Syndrome
Down Syndrome 		0.020 GeneticVariation disease BEFREE Interferon induction of (2'-5') oligoisoadenylate synthetase in diploid and trisomy 21 human fibroblasts: relation to dosage of the interferon receptor gene (IRFC). 6317538 1983
CUI: C0019196
Disease: Hepatitis C
Hepatitis C 		0.080 AlteredExpression disease BEFREE We investigated whether interferon receptor gene (IFNAR1 and IFNAR2 mRNA) expression in the liver before interferon therapy predicts long-term response to therapy in patients with genotype 2a or 2b HCV infection. 9563926 1998
CUI: C3830467
Disease: Disseminated Bacillus Calmette-Guerin infection
Disseminated Bacillus Calmette-Guerin infection 		0.010 GeneticVariation disease BEFREE Inactivating mutations of the gamma-interferon receptor lead to increased susceptibility to typical mycobacteria and disseminated BCG infection in homozygous children. 9597143 1998
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic 		0.040 AlteredExpression disease BEFREE Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. 10421402 1999
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.010 Biomarker disease BEFREE The overexpression found in ganglion cells suggests that IFN-R could be involved in the pathway of neuroblastoma differentiation. 9864419 1999
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.010 Biomarker disease BEFREE The overexpression found in ganglion cells suggests that IFN-R could be involved in the pathway of neuroblastoma differentiation. 9864419 1999
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.010 Biomarker disease BEFREE The overexpression found in ganglion cells suggests that IFN-R could be involved in the pathway of neuroblastoma differentiation. 9864419 1999
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.050 Biomarker disease BEFREE Expression of Hu-IFN-alphaR2 chain of type I interferon receptor in human hepatocellular carcinoma and non-cancerous tissues. 11078820 2000
CUI: C0019163
Disease: Hepatitis B
Hepatitis B 		0.340 AlteredExpression disease BEFREE Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. 11170061 2001
CUI: C0019196
Disease: Hepatitis C
Hepatitis C 		0.080 AlteredExpression disease BEFREE Co-infection was associated with lower IFNAR2 mRNA levels, higher levels of serum HCV RNA, and a poor IFN response, regardless of the HCV genotype. 11170061 2001
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic 		0.040 AlteredExpression disease BEFREE Intrahepatic mRNA levels of type-I interferon (IFN) receptor genes have been shown to correlate with the clinical efficacy of IFN therapy in patients with chronic hepatitis C. Recently, co-infection by serologically-silent hepatitis B virus (HBV) has been assumed to be associated with the poor IFN response in patients with chronic hepatitis C. The aim of this study was to investigate the relationship between the co-infection of serologically-silent HBV and type-I IFN receptor gene expression in the liver of patients with chronic hepatitis C. The intrahepatic mRNA levels of IFNAR2, one of the two subunits of the type-I IFN receptor, were quantified and compared with both the prevalence of HBV DNA and the hepatitis C virus (HCV) genotype in 45 patients with chronic hepatitis C, who were negative for hepatitis B surface antigen. 11170061 2001
CUI: C0275524
Disease: Coinfection
Coinfection 		0.010 AlteredExpression phenotype BEFREE Co-infection was associated with lower IFNAR2 mRNA levels, higher levels of serum HCV RNA, and a poor IFN response, regardless of the HCV genotype. 11170061 2001
CUI: C0019196
Disease: Hepatitis C
Hepatitis C 		0.080 AlteredExpression disease BEFREE 9-cis retinoic acid enhances the antiviral effect of interferon on hepatitis C virus replication through increased expression of type I interferon receptor. 12518169 2003
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.050 GeneticVariation disease BEFREE Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. 12618863 2003
CUI: C0024141
Disease: Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic 		0.040 Biomarker disease BEFREE Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. 12642605 2003
CUI: C0024131
Disease: Lupus Vulgaris
Lupus Vulgaris 		0.010 Biomarker disease BEFREE Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. 12642605 2003
CUI: C0024138
Disease: Lupus Erythematosus, Discoid
Lupus Erythematosus, Discoid 		0.010 Biomarker disease BEFREE Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. 12642605 2003
CUI: C0409974
Disease: Lupus Erythematosus
Lupus Erythematosus 		0.010 Biomarker disease BEFREE Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. 12642605 2003
CUI: C0019196
Disease: Hepatitis C
Hepatitis C 		0.080 AlteredExpression disease BEFREE HCV-RNA level: odds ratio 0.23, 95% CI 0.038-0.864; and IFNAR2 in liver: odds ratio 1.116, 95% CI 1.015-1.227). 14996348 2004
CUI: C0524910
Disease: Hepatitis C, Chronic
Hepatitis C, Chronic 		0.040 Biomarker disease BEFREE Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. 14996348 2004
CUI: C0023473
Disease: Myeloid Leukemia, Chronic
Myeloid Leukemia, Chronic 		0.020 AlteredExpression disease BEFREE Thus, the pretreatment protein and mRNA expression levels of IFNAR2 and their down-regulations during IFNalpha therapy correlate well with IFNalpha response in CML patients. 15287917 2004